Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aksys

This article was originally published in The Gray Sheet

Executive Summary

Firm raises $11.8 mil. in a private placement of 1.5 mil. shares to institutional investors. Lincolnshire, Illinois-based Aksys is conducting clinical trials of its PHD personal hemodialysis system and expects to submit a 510(k) by the end of October (1"The Gray Sheet" Jan. 10, In Brief). Proceeds will support pre-commercialization activities, including a planned ramp-up in sales staff and manufacturing. U.S. Bancorp Piper Jaffray was placement agent for the financing

You may also be interested in...



Aksys

Enrolls 24 patients in a six-month clinical study of its PHD personal hemodialysis system to support a future 510(k) submission to FDA. The three-phase trial is being conducted at dialysis clinics located in Washington, Missouri and Mississippi

EMA Stands By Suspension Of Ranitidine In EU After Re-Examination

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel